Milestone reflects the company’s continued impact in providing global pharmaceutical partners with reliable supply and enabling sustained patient access to life-saving therapies
Mississauga, Ontario (December 5, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrates the five-year anniversary of its Mississauga, Ontario, Canada facility, a key hub in the company’s North American operations and a cornerstone of its expanding international CDMO network. The milestone will be celebrated onsite with employees, partners, and community stakeholders.
Bora’s Mississauga facility, its North American headquarters, spans 170,000 square meters and was purpose-built for flexible, high-quality, cGMP drug manufacturing. Equipped with 18 highly configurable manufacturing modules, the site provides “best-fit” capabilities across development, manufacturing, packaging, and commercialization to support a wide range of prescription (Rx) and over-the-counter (OTC) oral solid dose (OSD), liquid, and semi-solid therapeutics. Bora recently announced a recent investment to install a high-performance filling line from Norden Machinery, enabling larger volumes at higher speeds with great flexibility, especially for dermatologic products.
“Bora’s Mississauga facility is more than a manufacturing site, it’s a highly skilled community of professionals advancing Canada’s life sciences ecosystem,” said J.D. Mowery, President, Bora Pharmaceuticals CDMO division. “We are proud of the growth, innovation, and customer value this team delivers every day. Their expertise and dedication enable reliable global supply, accelerates patient access to essential medicines, and strengthens Bora’s position as a trusted global CDMO partner. We’re thrilled to celebrate this five-year milestone with the Bora team.”
Over the past five years, Bora’s Mississauga site has become a vital anchor within Ontario’s growing life sciences ecosystem, creating jobs, expanding technical training opportunities, and generating direct and indirect economic impact for the region.
Since joining the Bora network in 2020, the facility has expanded both its technical capabilities and its customer base, becoming a strategic manufacturing partner for leading global pharmaceutical companies. Significant investments in new equipment and flexible manufacturing technologies have enabled the site to support 32 clients, advance 61 products, and deliver 60 development and technology-transfer projects, completing more than 400 project and development batches. These milestones reflect Mississauga’s growing role in ensuring high-quality, cGMP production and reliable delivery for critical drug programs worldwide.
“Congratulations to the Mississauga team on five impactful years as part of the Bora network,” said Gyan Singh, Senior Vice President of Operations at Azurity Pharmaceuticals. “The team consistently delivers on their commitments with high quality and technical excellence, making Bora a trusted and valued partner in Azurity’s journey.”
“Behind every milestone are the employees whose expertise brings Bora’s mission to life,” said John Lawrie, VP of Operations for Bora Pharmaceuticals. “Their commitment to quality, safety, and proactive customer support is what makes Mississauga a model of operational excellence within Bora’s global network.”
The Mississauga site is one of seven cGMP Bora manufacturing facilities across the United States, Canada, and Taiwan that together form a rapidly expanding CDMO platform and deliver drug products to more than 100 countries. The company continues to invest in its global network to meet rising demand for high-quality, flexible pharmaceutical development and commercial manufacturing services.
# # #
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologic, and sterile injectable pharmaceutical products. From its world-class sites in North America and Asia, Bora delivers drug products with unparalleled quality to more than 100 markets around the world. Bora Pharmaceuticals Co., Ltd. is publicly traded on the Taiwan Stock Exchange (TWSE: 6472). For more information, visit www.boracdmo.com.